Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter


Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive soLid maLignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent evidence indicates that PDAC is associated with frequent, altered cellular signaLing pathways. We review these key pathways as well as recent investigations in the area of pancreatic cancer stem cells. Unfortunately, most phase III randomized trials of targeted therapies have not shown a survival advantage in PDAC. However, there has been extensive laboratory and cLinical research in these areas which has revealed mechanisms of resistance involved in targeting PDAC and has provided insights into the ineffectiveness of current therapies. Current investigations will hopefully provide better insights into improved therapies and understanding of ways to overcome chemoresistance in PDAC. In this article, we discuss the current research exploring altered signaLing pathways in PDAC and potential therapeutic targets.

Original languageEnglish (US)
Title of host publicationPathobiology of Human Disease
Subtitle of host publicationA Dynamic Encyclopedia of Disease Mechanisms
PublisherElsevier Inc.
Number of pages9
ISBN (Electronic)9780123864567
ISBN (Print)9780123864574
StatePublished - Jan 1 2014
Externally publishedYes


  • Altered signaLing
  • Cancer stem cells
  • Cellular signaLing
  • Chemoresistance
  • CLinical trials
  • EGFR
  • Erlotinib
  • Gemcitabine
  • Hedgehog
  • Metastasis
  • Notch
  • Overcome resistance
  • Pancreatic cancer
  • Pancreatic ductal adenocarcinoma
  • PanIN
  • Ras
  • SignaLing pathways
  • Src
  • STAT3
  • Survival
  • Targeting
  • Therapeutic resistance
  • Transforming growth factor-β (TGF-β)
  • Wnt

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this